These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25041999)

  • 1. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
    Loi M; Becherini P; Emionite L; Giacomini A; Cossu I; Destefanis E; Brignole C; Di Paolo D; Piaggio F; Perri P; Cilli M; Pastorino F; Ponzoni M
    J Control Release; 2014 Oct; 192():157-66. PubMed ID: 25041999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
    Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
    J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy.
    Shen J; Song G; An M; Li X; Wu N; Ruan K; Hu J; Hu R
    Biomaterials; 2014 Jan; 35(1):316-26. PubMed ID: 24125776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway.
    Naumann I; Kappler R; von Schweinitz D; Debatin KM; Fulda S
    Clin Cancer Res; 2011 May; 17(10):3204-18. PubMed ID: 21459798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
    Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
    BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?
    de Wilt LH; Kroon J; Jansen G; de Jong S; Peters GJ; Kruyt FA
    Crit Rev Oncol Hematol; 2013 Mar; 85(3):363-72. PubMed ID: 22944363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
    Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
    Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
    An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
    Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.
    Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Jiang X
    Nanotechnology; 2011 Jul; 22(26):265105. PubMed ID: 21586819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
    Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
    J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
    Michaelis M; Fichtner I; Behrens D; Haider W; Rothweiler F; Mack A; Cinatl J; Doerr HW; Cinatl J
    Int J Oncol; 2006 Feb; 28(2):439-46. PubMed ID: 16391799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
    Sun L; Zhang L; Qian J; Yang J; Yi Q; Dong W; Wang M
    Leuk Res; 2012 Mar; 36(3):363-8. PubMed ID: 22000823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib.
    Furfaro AL; Piras S; Passalacqua M; Domenicotti C; Parodi A; Fenoglio D; Pronzato MA; Marinari UM; Moretta L; Traverso N; Nitti M
    Biochim Biophys Acta; 2014 Apr; 1842(4):613-22. PubMed ID: 24380881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.
    Conticello C; Adamo L; Vicari L; Giuffrida R; Iannolo G; Anastasi G; Caruso L; Moschetti G; Cupri A; Palumbo GA; Gulisano M; De Maria R; Giustolisi R; Di Raimondo F
    Acta Haematol; 2008; 120(1):19-30. PubMed ID: 18716397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells.
    De Miguel D; Gallego-Lleyda A; Ayuso JM; Pawlak A; Conde B; Ochoa I; Fernández LJ; Anel A; Martinez-Lostao L
    Recent Pat Anticancer Drug Discov; 2016; 11(2):197-214. PubMed ID: 26924736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.
    Wahl K; Siegemund M; Lehner F; Vondran F; Nüssler A; Länger F; Krech T; Kontermann R; Manns MP; Schulze-Osthoff K; Pfizenmaier K; Bantel H
    Hepatology; 2013 Feb; 57(2):625-36. PubMed ID: 22991197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment.
    Eriksson E; Wickström M; Perup LS; Johnsen JI; Eksborg S; Kogner P; Sävendahl L
    J Natl Cancer Inst; 2014 Mar; 106(3):djt459. PubMed ID: 24586107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model.
    Valentiner U; Haane C; Nehmann N; Schumacher U
    Anticancer Res; 2009 Apr; 29(4):1219-25. PubMed ID: 19414367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
    Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
    Luo P; Lin M; Li L; Yang B; He Q
    PLoS One; 2011; 6(11):e27298. PubMed ID: 22087283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.